Belarusian Healthcare Professionals’ Views on Monkeypox and Vaccine Hesitancy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Design
2.2. Participants
2.3. Instrument
2.4. Measures
2.5. Ethics
2.6. Analyses
3. Results
3.1. Demographic and Anamnestic Characteristics
3.2. Mpox Information Sources
3.3. Mpox-Related Perceived Knowledge
3.4. Mpox-Related Factual Knowledge
3.5. Correlation of Perceived and Factual Knowledge
3.6. Mpox Vaccine Acceptance
3.7. Correlates of Mpox Vaccine Acceptance
3.8. Mpox Vaccine Recommendations and Willingness to Pay
4. Discussion
4.1. Study Strengths
4.2. Study Limitations
4.3. Study Implications
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Moore, M.J.; Rathish, B.; Zahra, F. Mpox (Monkeypox); StatPearls: Treasure Island, FL, USA, 2023. [Google Scholar]
- Von Magnus, P.; Andersen, E.K.; Petersen, K.B.; Birch-Andersen, A. A Pox-Like Disease in Cynomolgus Monkeys. Acta Pathol. Microbiol. Scand. 1959, 46, 156–176. [Google Scholar] [CrossRef]
- Marennikova, S.S.; Seluhina, E.M.; Mal’ceva, N.N.; Cimiskjan, K.L.; Macevic, G.R. Isolation and Properties of the Causal Agent of a New Variola-like Disease (Monkeypox) in Man. Bull. World Health Organ. 1972, 46, 599. [Google Scholar] [PubMed]
- Harapan, H.; Ophinni, Y.; Megawati, D.; Frediansyah, A.; Mamada, S.S.; Salampe, M.; Bin Emran, T.; Winardi, W.; Fathima, R.; Sirinam, S.; et al. Monkeypox: A Comprehensive Review. Viruses 2022, 14, 2155. [Google Scholar] [CrossRef]
- World Health Organization (WHO). WHO Director-General’s Statement at the Press Conference Following IHR Emergency Committee Regarding the Multi-Country Outbreak of Monkeypox—23 July 2022. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022 (accessed on 10 December 2022).
- World Health Organization (WHO). Vaccines and Immunization for Monkeypox: Interim Guidance. Available online: https://www.who.int/publications/i/item/who-mpx-immunization-2022.1 (accessed on 10 August 2022).
- Alakunle, E.; Moens, U.; Nchinda, G.; Okeke, M.I. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. Viruses 2020, 12, 1257. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). 2022 Monkeypox Outbreak Global Map. Available online: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html (accessed on 21 October 2022).
- Ministry of Health: The Probability of Importing Monkeypox to Belarus Is Assessed as Low. Available online: https://www.belta.by/society/view/minzdrav-verojatnost-zavoza-ospy-obezjjan-v-belarus-otsenivaetsja-kak-nizkaja-503608-2022/ (accessed on 7 June 2023).
- Temsah, M.H.; Aljamaan, F.; Alenezi, S.; Alhasan, K.; Saddik, B.; Al-Barag, A.; Alhaboob, A.; Bahabri, N.; Alshahrani, F.; Alrabiaah, A.; et al. Monkeypox Caused Less Worry than COVID-19 among the General Population during the First Month of the WHO Monkeypox Alert: Experience from Saudi Arabia. Travel Med. Infect. Dis. 2022, 49, 102426. [Google Scholar] [CrossRef]
- Gallè, F.; Bianco, L.; Da Molin, G.; Mancini, R.; Sciacchitano, S.; Ferracuti, S.; Liguori, G.; Orsi, G.B.; Napoli, C. “Monkeypox: What Do You Know about That?” Italian Adults’ Awareness of a New Epidemic. Pathogens 2022, 11, 1285. [Google Scholar] [CrossRef] [PubMed]
- Lounis, M.; Riad, A. Monkeypox (MPOX)-Related Knowledge and Vaccination Hesitancy in Non-Endemic Countries: Concise Literature Review. Vaccines 2023, 11, 229. [Google Scholar] [CrossRef] [PubMed]
- Rosenstock, I.M. Health Belief Model. In Encyclopedia of Psychology; American Psychological Association: Washington, DC, USA, 2000; Volume 4, pp. 78–80. ISBN 1-55798-653-3. [Google Scholar]
- Wayne, W. LaMorte the Health Belief Model. Available online: https://sphweb.bumc.bu.edu/otlt/mph-modules/sb/behavioralchangetheories/behavioralchangetheories2.html (accessed on 11 August 2022).
- Rosenstock, I.M. The Health Belief Model and Preventive Health Behavior. Health Educ. Behav. 1974, 2, 354–386. [Google Scholar] [CrossRef]
- Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. UroToday Int. J. 2007, 335, 806–808. [Google Scholar] [CrossRef] [Green Version]
- Harvard Humanitarian Initiative Welcome to KoBoToolbox. Available online: https://support.kobotoolbox.org/welcome.html (accessed on 4 January 2022).
- Centers for Disease Control and Prevention, (CDC) Epi Info™ for Windows. Available online: https://www.cdc.gov/epiinfo/pc.html (accessed on 25 December 2020).
- Riad, A.; Drobov, A.; Rozmarinová, J.; Drapáčová, P.; Klugarová, J.; Dušek, L.; Pokorná, A.; Klugar, M. Monkeypox Knowledge and Vaccine Hesitancy of Czech Healthcare Workers: A Health Belief Model (HBM)-Based Study. Vaccines 2022, 10, 2022. [Google Scholar] [CrossRef]
- Belarus Health System Information. Available online: https://eurohealthobservatory.who.int/countries/belarus (accessed on 25 May 2023).
- Riccò, M.; Ferraro, P.; Camisa, V.; Satta, E.; Zaniboni, A.; Ranzieri, S.; Baldassarre, A.; Zaffina, S.; Marchesi, F. When a Neglected Tropical Disease Goes Global: Knowledge, Attitudes and Practices of Italian Physicians towards Monkeypox, Preliminary Results. Trop. Med. Infect. Dis. 2022, 7, 135. [Google Scholar] [CrossRef]
- Anonymous. High Acceptance of New Monkeypox Vaccine among GPs in Indonesia. PharmacoEconomics Outcomes News 2020, 862, 15. [Google Scholar] [CrossRef]
- Harapan, H.; Setiawan, A.M.; Yufika, A.; Anwar, S.; Wahyuni, S.; Asrizal, F.W.; Sufri, M.R.; Putra, R.P.; Wijayanti, N.P.; Salwiyadi, S.; et al. Knowledge of Human Monkeypox Viral Infection among General Practitioners: A Cross-Sectional Study in Indonesia. Pathog. Glob. Health 2020, 114, 68. [Google Scholar] [CrossRef] [PubMed]
- Harapan, H.; Setiawan, A.M.; Yufika, A.; Anwar, S.; Wahyuni, S.; Asrizal, F.W.; Sufri, M.R.; Putra, R.P.; Wijayanti, N.P.; Salwiyadi, S.; et al. Physicians’ Willingness to Be Vaccinated with a Smallpox Vaccine to Prevent Monkeypox Viral Infection: A Cross-Sectional Study in Indonesia. Clin. Epidemiol. Glob. Health 2020, 8, 1259–1263. [Google Scholar] [CrossRef] [PubMed]
- Proton Technologies AG General Data Protection Regulation (GDPR) Compliance Guidelines. Available online: https://gdpr.eu/ (accessed on 1 May 2020).
- WMA. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA J. Am. Med. Assoc. 2013, 310, 2191–2194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- SPSS Inc. IBM SPSS Statistics 28. Available online: https://www.ibm.com/support/pages/ibm-spss-statistics-28-documentation (accessed on 7 January 2023).
- Hong, J.; Pan, B.; Jiang, H.-J.; Zhang, Q.-M.; Xu, X.-W.; Jiang, H.; Ye, J.; Cui, Y.; Yan, X.-J.; Zhai, X.-F.; et al. The Willingness of Chinese Healthcare Workers to Receive Monkeypox Vaccine and Its Independent Predictors: A Cross-Sectional Survey. J. Med. Virol. 2023, 95, e28294. [Google Scholar] [CrossRef] [PubMed]
- Mahameed, H.; Al-Mahzoum, K.; Alraie, L.A.; Aburumman, R.; Al-Naimat, H.; Alhiary, S.; Barakat, M.; Al-Tammemi, A.B.; Salim, N.A.; Sallam, M. Previous Vaccination History and Psychological Factors as Significant Predictors of Willingness to Receive Mpox Vaccination and a Favorable Attitude towards Compulsory Vaccination. Vaccines 2023, 11, 897. [Google Scholar] [CrossRef]
- Joseph Berdida, D.E. Population-Based Survey of Human Monkeypox Disease Knowledge in the Philippines: An Online Cross-Sectional Study. J. Adv. Nurs. 2023, 79, 2684–2694. [Google Scholar] [CrossRef]
- Alshahrani, N.Z.; Alzahrani, F.; Alarifi, A.M.; Algethami, M.R.; Alhumam, M.N.; Ayied, H.A.M.; Awan, A.Z.; Almutairi, A.F.; Bamakhrama, S.A.; Almushari, B.S.; et al. Assessment of Knowledge of Monkeypox Viral Infection among the General Population in Saudi Arabia. Pathogens 2022, 11, 904. [Google Scholar] [CrossRef]
- Baekkeskov, E. Same Threat, Different Responses: Experts Steering Politicians and Stakeholders in 2009 H1N1 Vaccination Policy-Making. Public Adm. 2016, 94, 299–315. [Google Scholar] [CrossRef]
- Ozisik, L.; Tanriover, M.D.; Altınel, S.; Unal, S. Vaccinating Healthcare Workers: Level of Implementation, Barriers and Proposal for Evidence-Based Policies in Turkey. Hum. Vaccines Immunother. 2017, 13, 1198–1206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paul, K.T.; Loer, K. Contemporary Vaccination Policy in the European Union: Tensions and Dilemmas. J. Public Health Policy 2019, 40, 166–179. [Google Scholar] [CrossRef] [PubMed]
- Holt, E. Health Workers in Belarus Facing Repression. Lancet 2021, 398, 377. [Google Scholar] [CrossRef]
- Larson, H.J.; Clarke, R.M.; Jarrett, C.; Eckersberger, E.; Levine, Z.; Schulz, W.S.; Paterson, P. Measuring Trust in Vaccination: A Systematic Review. Hum. Vaccines Immunother. 2018, 14, 1599–1609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kummitha, R.K.R. Smart Technologies for Fighting Pandemics: The Techno- and Human- Driven Approaches in Controlling the Virus Transmission. Gov. Inf. Q. 2020, 37, 101481. [Google Scholar] [CrossRef] [PubMed]
- Winters, M.; Malik, A.A.; Omer, S.B. Attitudes towards Monkeypox Vaccination and Predictors of Vaccination Intentions among the US General Public. PLoS ONE 2022, 17, e0278622. [Google Scholar] [CrossRef]
- Park, C.-Y. News Media Exposure and Self-Perceived Knowledge: The Illusion of Knowing. Int. J. Public Opin. Res. 2001, 13, 419–425. [Google Scholar] [CrossRef]
- Lipkus, I.M.; Eissenberg, T.; Schwartz-Bloom, R.D.; Prokhorov, A.V.; Levy, J. Relationships among Factual and Perceived Knowledge of Harms of Waterpipe Tobacco, Perceived Risk, and Desire to Quit among College Users. J. Health Psychol. 2013, 19, 1525–1535. [Google Scholar] [CrossRef] [Green Version]
- Ladwig, P.; Dalrymple, K.E.; Brossard, D.; Scheufele, D.A.; Corley, E.A. Perceived Familiarity or Factual Knowledge? Comparing Operationalizations of Scientific Understanding. Sci. Public Policy 2012, 39, 761–774. [Google Scholar] [CrossRef] [Green Version]
- González-Olmo, M.J.; Ortega-Martínez, A.R.; Delgado-Ramos, B.; Romero-Maroto, M.; Carrillo-Diaz, M. Perceived Vulnerability to Coronavirus Infection: Impact on Dental Practice. Braz. Oral. Res. 2020, 34, e044. [Google Scholar] [CrossRef]
- El-Deirawi, K.M.; Zuraikat, N. Registered Nurses’ Actual and Perceived Knowledge of Diabetes Mellitus. J. Nurses Staff. Dev. 2001, 19, 95–100. [Google Scholar] [CrossRef]
- Drass, J.A.; Muir-Nash, J.; Boykin, P.C.; Turek, J.M.; Baker, K.L. Perceived and Actual Level of Knowledge of Diabetes Mellitus among Nurses. Diabetes Care 1989, 12, 351–356. [Google Scholar] [CrossRef]
- Sherbino, J.; Dore, K.L.; Wood, T.J.; Young, M.E.; Gaissmaier, W.; Kreuger, S.; Norman, G.R. The Relationship between Response Time and Diagnostic Accuracy. Acad. Med. 2012, 87, 785–791. [Google Scholar] [CrossRef] [PubMed]
- Alsanafi, M.; Al-Mahzoum, K.; Sallam, M. Monkeypox Knowledge and Confidence in Diagnosis and Management with Evaluation of Emerging Virus Infection Conspiracies among Health Professionals in Kuwait. Pathogens 2022, 11, 994. [Google Scholar] [CrossRef] [PubMed]
- Malaeb, D.; Sallam, M.; Salim, N.A.; Dabbous, M.; Younes, S.; Nasrallah, Y.; Iskandar, K.; Matta, M.; Obeid, S.; Hallit, S.; et al. Knowledge, Attitude and Conspiracy Beliefs of Healthcare Workers in Lebanon towards Monkeypox. Trop. Med. Infect. Dis. 2023, 8, 81. [Google Scholar] [CrossRef] [PubMed]
- Sallam, M.; Al-Mahzoum, K.; Al-Tammemi, A.B.; Alkurtas, M.; Mirzaei, F.; Kareem, N.; Al-Naimat, H.; Jardaneh, L.; Al-Majali, L.; AlHadidi, A.; et al. Assessing Healthcare Workers’ Knowledge and Their Confidence in the Diagnosis and Management of Human Monkeypox: A Cross-Sectional Study in a Middle Eastern Country. Healthcare 2022, 10, 1722. [Google Scholar] [CrossRef]
- Alshahrani, N.Z.; Algethami, M.R.; Alarifi, A.M.; Alzahrani, F.; Alshehri, E.A.; Alshehri, A.M.; Sheerah, H.A.; Abdelaal, A.; Sah, R.; Rodriguez-Morales, A.J. Knowledge and Attitude Regarding Monkeypox Virus among Physicians in Saudi Arabia: A Cross-Sectional Study. Vaccines 2022, 10, 2099. [Google Scholar] [CrossRef]
- Sahin, T.K.; Erul, E.; Aksun, M.S.; Sonmezer, M.C.; Unal, S.; Akova, M. Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study. Vaccines 2023, 11, 19. [Google Scholar] [CrossRef]
- Lounis, M.; Bencherit, D.; Abdelhadi, S. Knowledge and Awareness of Algerian Healthcare Workers about Human Monkeypox and Their Attitude toward Its Vaccination: An Online Cross-Sectional Survey. Vacunas 2023, 24, 122–127. [Google Scholar] [CrossRef]
- Riad, A.; Drobov, A.; Rozmarinová, J.; Drapáčová, P.; Klugarová, J.; Dušek, L.; Pokorna, A.; Klugar, M. Monkeypox (Mpox)-Related Knowledge and Vaccine Hesitancy among Czech Healthcare Professionals. Popul. Med. 2023, 5, A2033. [Google Scholar] [CrossRef]
- Caycho-Rodríguez, T.; Tomás, J.M.; Vilca, L.W.; Carbajal-León, C.; Gallegos, M.; Reyes-Bossio, M.; Oré-Kovacs, N.; Muñoz-del-Carpio-Toia, Á.; Torales, J.; Barria-Asenjo, N.A.; et al. Relationship Between Fear of Monkeypox and Intention to Be Vaccinated Against Monkeypox in a Peruvian Sample. The Mediating Role of Conspiracy Beliefs About Monkeypox. Eval. Health Prof. 2023; online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Ulloque-Badaracco, J.R.; Alarcón-Braga, E.A.; Hernandez-Bustamante, E.A.; Al-kassab-Córdova, A.; Benites-Zapata, V.A.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. Acceptance towards Monkeypox Vaccination: A Systematic Review and Meta-Analysis. Pathogens 2022, 11, 1248. [Google Scholar] [CrossRef] [PubMed]
- Ghazy, R.M.; Yazbek, S.; Gebreal, A.; Hussein, M.; Addai, S.A.; Mensah, E.; Sarfo, M.; Kofi, A.; AL-Ahdal, T.; Eshun, G. Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action. Vaccines 2023, 11, 240. [Google Scholar] [CrossRef] [PubMed]
- Gagneux-Brunon, A.; Dauby, N.; Launay, O.; Botelho-Nevers, E. Intentions to Get Vaccinated against Monkeypox in Healthcare Workers in France and Belgium Correlates with Attitudes toward COVID-19 Vaccination. medRxiv 2022. [Google Scholar] [CrossRef]
- United Nations in Belarus Gender Equity at the Centre of UN System’s Work in Belarus. Available online: https://belarus.un.org/en/227258-gender-equity-centre-un-system%E2%80%99s-work-belarus (accessed on 7 June 2023).
Variable | Outcome | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
Gender | Female | 24 (92.3%) | 42 (95.5%) | 70 (94.6%) | 136 (94.4%) | 0.789 |
Male | 2 (7.7%) | 2 (4.5%) | 4 (5.4%) | 8 (5.6%) | ||
Sex | Heterosexual | 24 (92.3%) | 42 (95.5%) | 67 (90.5%) | 133 (92.4%) | 0.482 |
Homosexual | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | ||
Bisexual | 2 (7.7%) | 0 (0%) | 4 (5.4%) | 6 (4.2%) | ||
Other | 0 (0%) | 2 (4.5%) | 2 (2.7%) | 4 (2.8%) | ||
Marital Status | Single | 5 (19.2%) | 7 (15.9%) | 14 (18.9%) | 26 (18.1%) | 0.008 |
Married | 16 (61.5%) | 36 (81.8%) | 59 (79.7%) | 111 (77.1%) | ||
Widowed | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | ||
Divorced | 5 (19.2%) | 1 (2.3%) | 0 (0%) | 6 (4.2%) | ||
Age Group | ≤31 years old | 9 (34.6%) | 25 (56.8%) | 44 (59.5%) | 78 (54.2%) | 0.084 |
>31 years old | 17 (65.4%) | 19 (43.2%) | 30 (40.5%) | 66 (45.8%) | ||
Have Children? | No | 8 (30.8%) | 16 (36.4%) | 33 (44.6%) | 57 (39.6%) | 0.404 |
Yes | 18 (69.2%) | 28 (63.6%) | 41 (55.4%) | 87 (60.4%) | ||
Profession | Medical HCPs | 15 (57.7%) | 36 (81.8%) | 61 (82.4%) | 112 (77.8%) | 0.025 |
Allied HCPs | 11 (42.3%) | 8 (18.2%) | 13 (17.6%) | 32 (22.2%) | ||
Provide Care? | No | 21 (80.8%) | 37 (84.1%) | 54 (73%) | 112 (77.8%) | 0.343 |
Yes | 5 (19.2%) | 7 (15.9%) | 20 (27%) | 32 (22.2%) |
Variable | Outcome | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
Chronic Diseases | Bowel Disease | 5 (19.2%) | 6 (13.6%) | 10 (13.5%) | 21 (14.6%) | 0.773 |
Thyroid Disease | 3 (11.5%) | 5 (11.4%) | 9 (12.2%) | 17 (11.8%) | 1.000 | |
Ophthalmologic Disease | 1 (3.8%) | 4 (9.1%) | 8 (10.8%) | 13 (9%) | 0.680 | |
Allergy | 2 (7.7%) | 2 (4.5%) | 7 (9.5%) | 11 (7.6%) | 0.643 | |
Cardiovascular Disease | 1 (3.8%) | 2 (4.5%) | 5 (6.8%) | 8 (5.6%) | 1.000 | |
Renal Disorders | 2 (7.7%) | 1 (2.3%) | 4 (5.4%) | 7 (4.9%) | 0.595 | |
Chronic Hypertension | 2 (7.7%) | 0 (0%) | 3 (4.1%) | 5 (3.5%) | 0.158 | |
Neurologic Disease | 2 (7.7%) | 1 (2.3%) | 0 (0%) | 3 (2.1%) | 0.062 | |
Blood Disease | 0 (0%) | 1 (2.3%) | 1 (1.4%) | 2 (1.4%) | 1.000 | |
Cancer | 0 (0%) | 0 (0%) | 2 (2.7%) | 2 (1.4%) | 0.684 | |
Rheumatoid Arthritis | 1 (3.8%) | 1 (2.3%) | 0 (0%) | 2 (1.4%) | 0.235 | |
Asthma | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
Diabetes Mellitus type-I | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
Diabetes Mellitus type-II | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
Hepatologic Disease | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
Total | 12 (46.2%) | 19 (43.2%) | 29 (39.2%) | 60 (41.7%) | 0.801 | |
Medications | Thyroid Hormones | 2 (7.7%) | 6 (13.6%) | 3 (4.1%) | 11 (7.6%) | 0.155 |
Hormonal Drugs | 0 (0%) | 4 (9.1%) | 4 (5.4%) | 8 (5.6%) | 0.297 | |
Antihypertensives | 1 (3.8%) | 1 (2.3%) | 3 (4.1%) | 5 (3.5%) | 1.000 | |
Contraceptives | 1 (3.8%) | 1 (2.3%) | 3 (4.1%) | 5 (3.5%) | 1.000 | |
Antidiabetics | 1 (3.8%) | 1 (2.3%) | 1 (1.4%) | 3 (2.1%) | 0.756 | |
Antihistamines | 0 (0%) | 1 (2.3%) | 1 (1.4%) | 2 (1.4%) | 1.000 | |
Immunosuppressives | 1 (3.8%) | 1 (2.3%) | 0 (0%) | 2 (1.4%) | 0.235 | |
Anticoagulants | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
NSAIDs | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
Other Medications | 0 (0%) | 2 (15.4%) | 2 (12.5%) | 4 (12.1%) | 1.000 | |
Total | 4 (15.4%) | 13 (29.5%) | 16 (21.6%) | 33 (22.9%) | 0.368 | |
COVID-19 Vaccine | One Dose | 1 (3.8%) | 1 (2.3%) | 2 (2.7%) | 4 (2.8%) | 1.000 |
Two Doses | 5 (19.2%) | 17 (38.6%) | 22 (29.7%) | 44 (30.6%) | 0.229 | |
Three Doses | 7 (26.9%) | 12 (27.3%) | 23 (31.1%) | 42 (29.2%) | 0.873 | |
Four Doses | 2 (7.7%) | 9 (20.5%) | 11 (14.9%) | 22 (15.3%) | 0.369 | |
≥Five Doses | 1 (3.8%) | 0 (0%) | 3 (4.1%) | 4 (2.8%) | 0.399 | |
Total | 16 (61.5%) | 39 (88.6%) | 61 (82.4%) | 116 (80.6%) | 0.018 | |
Flu Vaccine | No | 10 (38.5%) | 10 (22.7%) | 7 (9.5%) | 27 (18.8%) | 0.004 |
Yes | 16 (61.5%) | 34 (77.3%) | 67 (90.5%) | 117 (81.3%) | ||
Recent Flu Vaccine | No | 6 (37.5%) | 13 (38.2%) | 30 (44.8%) | 49 (41.9%) | 0.762 |
Yes | 10 (62.5%) | 21 (61.8%) | 37 (55.2%) | 68 (58.1%) | ||
Smallpox Vaccine | No | 19 (73.1%) | 34 (77.3%) | 64 (86.5%) | 117 (81.3%) | 0.199 |
Yes | 7 (26.9%) | 10 (22.7%) | 10 (13.5%) | 27 (18.8%) |
Variable | Outcome | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
Undergraduate Curriculum | No | 19 (73.1%) | 36 (81.8%) | 59 (79.7%) | 114 (79.2%) | 0.675 |
Yes | 7 (26.9%) | 8 (18.2%) | 15 (20.3%) | 30 (20.8%) | ||
Commonly Utilised Information Sources | Social Media | 12 (46.2%) | 25 (56.8%) | 53 (71.6%) | 90 (62.5%) | 0.045 |
WHO | 15 (57.7%) | 24 (54.5%) | 45 (60.8%) | 84 (58.3%) | 0.798 | |
Ministry of Health | 9 (34.6%) | 21 (47.7%) | 38 (51.4%) | 68 (47.2%) | 0.338 | |
News Portals | 7 (26.9%) | 13 (29.5%) | 28 (37.8%) | 48 (33.3%) | 0.487 | |
Professional Societies | 10 (38.5%) | 9 (20.5%) | 18 (24.3%) | 37 (25.7%) | 0.232 | |
Public Health Authorities | 8 (30.8%) | 10 (22.7%) | 14 (18.9%) | 32 (22.2%) | 0.456 | |
Scholarly Journals | 4 (15.4%) | 8 (18.2%) | 18 (24.3%) | 30 (20.8%) | 0.548 | |
ECDC | 4 (15.4%) | 7 (15.9%) | 13 (17.6%) | 24 (16.7%) | 1.000 | |
US CDC | 3 (11.5%) | 5 (11.4%) | 14 (18.9%) | 22 (15.3%) | 0.528 | |
Pharmaceutical Industry | 1 (3.8%) | 4 (9.1%) | 5 (6.8%) | 10 (6.9%) | 0.752 | |
Total (0–10) | 2.8 ± 1.6 | 2.9 ± 1.7 | 3.3 ± 1.9 | 3.1 ± 1.8 | 0.337 | |
Level of Confidence (1–7) | US CDC | 6.3 ± 0.6 | 6.0 ± 0.0 | 6.1 ± 0.4 | 6.1 ± 0.4 | 0.427 |
Professional Societies | 6.1 ± 0.6 | 6.0 ± 0.5 | 6.0 ± 0.6 | 6.0 ± 0.6 | 0. 887 | |
ECDC | 6.0 ± 0.8 | 6.0 ± 0.0 | 5.9 ± 0.6 | 5.9 ± 0.5 | 0.744 | |
Scholarly Journals | 5.5 ± 0.6 | 5.9 ± 0.4 | 6.1 ± 0.4 | 5.9 ± 0.5 | 0.072 | |
WHO | 5.8 ± 0.7 | 6.0 ± 0.6 | 5.8 ± 0.8 | 5.8 ± 0.7 | 0.478 | |
Public Health Authorities | 4.5 ± 1.4 | 5.1 ± 0.9 | 4.8 ± 1.3 | 4.8 ± 1.2 | 0.700 | |
News Portals | 4.4 ± 1.5 | 4.9 ± 0.9 | 4.6 ± 0.8 | 4.7 ± 0.9 | 0.747 | |
Social Media | 4.9 ± 1.2 | 4.7 ± 0.9 | 4.6 ± 1.0 | 4.7 ± 1.0 | 0.425 | |
Pharmaceutical Industry | 4.0 ± 0.0 | 4.5 ± 0.6 | 4.8 ± 1.3 | 4.6 ± 1.0 | 0.696 | |
Ministry of Health | 4.1 ± 1.8 | 5.0 ± 0.9 | 4.3 ± 1.4 | 4.5 ± 1.4 | 0.205 |
Variable | Outcome | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
Perceived Knowledge | Epidemiology: (1–5) | 2.7 ± 0.8 | 2.4 ± 0.9 | 2.6 ± 0.9 | 2.6 ± 0.9 | 0.317 |
Clinical Presentation: (1–5) | 3.0 ± 0.8 | 2.6 ± 1.1 | 2.9 ± 0.9 | 2.8 ± 1.0 | 0.399 | |
Transmission: (1–5) | 3.2 ± 1.0 | 2.7 ± 1.1 | 3.1 ± 1.0 | 3.0 ± 1.0 | 0.087 | |
Prevention: (1–5) | 2.5 ± 0.9 | 2.4 ± 0.9 | 2.6 ± 0.9 | 2.5 ± 0.9 | 0.546 | |
Treatment: (1–5) | 2.3 ± 0.8 | 2.3 ± 1.0 | 2.5 ± 0.9 | 2.4 ± 0.9 | 0.444 | |
Factual Knowledge: Epidemiology | Incubation Period | 13 (50%) | 26 (59.1%) | 46 (62.2%) | 85 (59%) | 0.555 |
Case-Fatality Ratio | 13 (50%) | 23 (52.3%) | 50 (67.6%) | 86 (59.7%) | 0.140 | |
Endemic Region | 20 (76.9%) | 30 (68.2%) | 52 (70.3%) | 102 (70.8%) | 0.731 | |
Total (0–3) | 1.8 ± 1.0 | 1.8 ± 1.0 | 2.0 ± 1.0 | 1.9 ± 1.0 | 0.408 | |
Factual Knowledge: Clinical Presentation | Clinical Symptoms | 24 (92.3%) | 41 (93.2%) | 66 (89.2%) | 131 (91%) | 0.800 |
Differential Diagnosis | 14 (53.8%) | 25 (56.8%) | 37 (50%) | 76 (52.8%) | 0.768 | |
Lesion Locations | 16 (61.5%) | 35 (79.5%) | 52 (70.3%) | 103 (71.5%) | 0.257 | |
Total (0–5) | 3.2 ± 1.4 | 3.1 ± 1.3 | 3.1 ± 1.4 | 3.1 ± 1.3 | 0.851 | |
Factual Knowledge: Transmission | Transmission Pathways | 25 (96.2%) | 40 (90.9%) | 68 (91.9%) | 133 (92.4%) | 0.839 |
Vertical Transmission | 14 (53.8%) | 18 (40.9%) | 20 (27%) | 52 (36.1%) | 0.096 | |
Sexual Transmission | 19 (73.1%) | 25 (56.8%) | 51 (68.9%) | 95 (66%) | 0.285 | |
Total (0–4) | 2.9 ± 1.0 | 2.6 ± 1.2 | 2.4 ± 1.0 | 2.5 ± 1.1 | 0.179 | |
Factual Knowledge: Prevention | Vaccine Availability | 5 (19.2%) | 9 (20.5%) | 20 (27%) | 34 (23.6%) | 0.607 |
Pre-exposure Prophylaxis | 20 (76.9%) | 31 (70.5%) | 56 (75.7%) | 107 (74.3%) | 0.776 | |
Cross-immunisation | 19 (73.1%) | 28 (63.6%) | 55 (74.3%) | 102 (70.8%) | 0.449 | |
Total (0–4) | 2.0 ± 1.2 | 2.1 ± 1.2 | 2.2 ± 1.2 | 2.1 ± 1.2 | 0.661 | |
Factual Knowledge: Treatment | Treatment Availability | 4 (15.4%) | 9 (20.5%) | 15 (20.3%) | 28 (19.4%) | 0.846 |
Medications List | 4 (15.4%) | 5 (11.4%) | 16 (21.6%) | 25 (17.4%) | 0.391 | |
Prognosis | 8 (30.8%) | 17 (38.6%) | 30 (40.5%) | 55 (38.2%) | 0.676 | |
Total (0–4) | 0.7 ± 0.7 | 0.7 ± 0.8 | 0.9 ± 1.0 | 0.8 ± 0.9 | 0.722 |
Perceived Knowledge | |||||||
---|---|---|---|---|---|---|---|
Epidemiology | Clinical Presentation | Transmission | Prevention | Treatment | |||
Factual Knowledge | Epidemiology | rho | 0.428 | 0.400 | 0.413 | 0.342 | 0.356 |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
Clinical Presentation | rho | 0.309 | 0.344 | 0.351 | 0.184 | 0.181 | |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
Transmission | rho | 0.274 | 0.342 | 0.333 | 0.272 | 0.205 | |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
Prevention | rho | 0.280 | 0.298 | 0.344 | 0.393 | 0.287 | |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
Treatment | rho | 0.239 | 0.260 | 0.219 | 0.325 | 0.282 | |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
Overall Score | rho | 0.439 | 0.481 | 0.494 | 0.426 | 0.380 | |
p. | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Category | Item | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
Perceived Susceptibility | 1. due to my occupation. | 2.4 ± 1.2 | 2.8 ± 1.0 | 3.1 ± 1.1 | 2.9 ± 1.1 | 0.016 |
2. due to lifestyle and health status. | 2.2 ± 1.0 | 2.3 ± 1.0 | 2.2 ± 0.9 | 2.2 ± 0.9 | 0.673 | |
3. not vaccinated vs. smallpox. | 2.5 ± 0.9 | 2.9 ± 1.0 | 3.0 ± 1.2 | 2.9 ± 1.1 | 0.148 | |
Overall Score (3–15) | 7.1 ± 2.6 | 8.0 ± 2.3 | 8.3 ± 2.5 | 8.0 ± 2.5 | 0.126 | |
Perceived Severity | 1. I will be very sick. | 2.5 ± 1.0 | 2.9 ± 0.9 | 2.8 ± 0.8 | 2.8 ± 0.9 | 0.137 |
2. I may require hospitalisation. | 3.0 ± 1.2 | 3.2 ± 0.9 | 3.3 ± 0.9 | 3.2 ± 0.9 | 0.357 | |
3. I might die. | 2.7 ± 1.1 | 3.2 ± 0.9 | 3.0 ± 0.9 | 3.0 ± 1.0 | 0.047 | |
Overall Score (3–15) | 8.2 ± 2.8 | 9.3 ± 2.4 | 9.0 ± 2.0 | 8.9 ± 2.3 | 0.117 | |
Perceived Benefits | 1. protected from getting infected. | 2.4 ± 1.1 | 3.3 ± 0.8 | 3.3 ± 1.2 | 3.2 ± 1.1 | <0.001 |
2. protected from serious complications. | 2.9 ± 1.2 | 3.7 ± 0.8 | 4.2 ± 0.7 | 3.8 ± 1.0 | <0.001 | |
3. protect my patients and family. | 2.7 ± 1.1 | 3.4 ± 0.9 | 4.0 ± 0.8 | 3.6 ± 1.0 | <0.001 | |
Overall Score (3–15) | 8.0 ± 3.1 | 10.5 ± 2.2 | 11.5 ± 2.0 | 10.6 ± 2.6 | <0.001 | |
Perceived Barriers | 1. availability of mpox vaccine. | 2.6 ± 1.1 | 3.1 ± 1.0 | 3.8 ± 1.1 | 3.4 ± 1.2 | <0.001 |
2. safety of mpox vaccine. | 3.0 ± 1.2 | 3.2 ± 1.0 | 3.2 ± 1.1 | 3.2 ± 1.1 | 0.768 | |
3. effectiveness of mpox vaccine. | 3.3 ± 1.2 | 3.2 ± 0.9 | 3.0 ± 1.1 | 3.1 ± 1.1 | 0.542 | |
Overall Score (3–15) | 8.9 ± 2.4 | 9.5 ± 2.3 | 10.0 ± 2.5 | 9.6 ± 2.4 | 0.134 | |
Cues to Action | 1. mandated by the employer. | 2.3 ± 1.1 | 2.8 ± 1.0 | 2.9 ± 1.2 | 2.8 ± 1.1 | 0.079 |
2. recommended by health authorities. | 2.6 ± 1.1 | 3.4 ± 0.8 | 3.5 ± 1.1 | 3.3 ± 1.1 | <0.001 | |
3. reliable evidence on eff. and safety. | 3.5 ± 1.3 | 4.0 ± 0.7 | 4.4 ± 0.9 | 4.1 ± 1.0 | <0.001 | |
Overall Score (3–15) | 8.4 ± 2.9 | 10.3 ± 1.6 | 10.8 ± 2.3 | 10.2 ± 2.4 | <0.001 |
Perceived Susceptibility | Perceived Severity | Perceived Benefits | Perceived Barriers | Cues to Action | Acceptance | ||
---|---|---|---|---|---|---|---|
Perceived Susceptibility | rho | 1.000 | 0.222 | 0.112 | 0.112 | −0.004 | 0.111 |
p. | 0.007 | 0.180 | 0.181 | 0.967 | 0.185 | ||
Perceived Severity | rho | 0.222 | 1.000 | 0.169 | 0.189 | 0.092 | 0.059 |
p. | 0.007 | 0.042 | 0.023 | 0.270 | 0.481 | ||
Perceived Benefits | rho | 0.112 | 0.169 | 1.000 | 0.171 | 0.456 | 0.451 |
p. | 0.180 | 0.042 | 0.041 | <0.001 | <0.001 | ||
Perceived Barriers | rho | 0.112 | 0.189 | 0.171 | 1.000 | 0.072 | 0.102 |
p. | 0.181 | 0.023 | 0.041 | 0.390 | 0.224 | ||
Cues to Action | rho | −0.004 | 0.092 | 0.456 | 0.072 | 1.000 | 0.349 |
p. | 0.967 | 0.270 | <0.001 | 0.390 | <0.001 | ||
Acceptance | rho | 0.111 | 0.059 | 0.451 | 0.102 | 0.349 | 1.000 |
p. | 0.185 | 0.481 | <0.001 | 0.224 | <0.001 |
Variable | Outcome | Mpox VAX Rejection (n = 26) | Mpox VAX Hesitancy (n = 44) | Mpox VAX Acceptance (n = 74) | Total (n = 144) | p. |
---|---|---|---|---|---|---|
I am willing/interested in recommending mpox vaccination to my patients, family members, and friends, especially those at risk. | Strongly disagree | 7 (26.9%) | 1 (2.3%) | 0 (0%) | 8 (5.6%) | <0.001 |
Disagree | 10 (38.5%) | 0 (0%) | 0 (0%) | 10 (6.9%) | <0.001 | |
Not sure | 5 (19.2%) | 30 (68.2%) | 4 (5.4%) | 39 (27.1%) | <0.001 | |
Agree | 3 (11.5%) | 12 (27.3%) | 48 (64.9%) | 63 (43.8%) | <0.001 | |
Strongly agree | 1 (3.8%) | 1 (2.3%) | 22 (29.7%) | 24 (16.7%) | <0.001 | |
Total (µ ± SD) | 2.3 ± 1.1 | 3.3 ± 0.6 | 4.2 ± 0.5 | 3.6 ± 1.0 | <0.001 | |
How much would you like to pay for the mpox vaccine shot as a personal expense? | It should be free. | 15 (57.7%) | 13 (29.5%) | 3 (4.1%) | 31 (21.5%) | 0.001 |
<BYN 24.7/dose | 3 (11.5%) | 14 (31.8%) | 24 (32.4%) | 41 (28.5%) | 0.107 | |
BYN 24.71–121.10/dose | 8 (30.8%) | 16 (36.4%) | 44 (59.5%) | 68 (47.2%) | 0.009 | |
BYN 121.11–244.67/dose | 0 (0%) | 1 (2.3%) | 2 (2.7%) | 3 (2.1%) | 1.000 | |
≥BYN 244.68/dose | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
What is the optimal price of the mpox vaccine for the public? | It should be free. | 14 (53.8%) | 14 (31.8%) | 23 (31.1%) | 51 (35.4%) | 0.095 |
<BYN 24.7/dose | 8 (30.8%) | 19 (43.2%) | 30 (40.5%) | 57 (39.6%) | 0.574 | |
BYN 24.71–121.10/dose | 4 (15.4%) | 11 (25%) | 21 (28.4%) | 36 (25%) | 0.421 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Riad, A.; Rybakova, N.; Dubatouka, N.; Zankevich, I.; Klugar, M.; Koščík, M.; Drobov, A. Belarusian Healthcare Professionals’ Views on Monkeypox and Vaccine Hesitancy. Vaccines 2023, 11, 1368. https://doi.org/10.3390/vaccines11081368
Riad A, Rybakova N, Dubatouka N, Zankevich I, Klugar M, Koščík M, Drobov A. Belarusian Healthcare Professionals’ Views on Monkeypox and Vaccine Hesitancy. Vaccines. 2023; 11(8):1368. https://doi.org/10.3390/vaccines11081368
Chicago/Turabian StyleRiad, Abanoub, Nadzeya Rybakova, Nadzeya Dubatouka, Ina Zankevich, Miloslav Klugar, Michal Koščík, and Anton Drobov. 2023. "Belarusian Healthcare Professionals’ Views on Monkeypox and Vaccine Hesitancy" Vaccines 11, no. 8: 1368. https://doi.org/10.3390/vaccines11081368
APA StyleRiad, A., Rybakova, N., Dubatouka, N., Zankevich, I., Klugar, M., Koščík, M., & Drobov, A. (2023). Belarusian Healthcare Professionals’ Views on Monkeypox and Vaccine Hesitancy. Vaccines, 11(8), 1368. https://doi.org/10.3390/vaccines11081368